Amgen: Biotech Value
Shares of this biotechnology giant have suffered -- yet the company's pipeline and growth strategy look as healthy as ever.
Sometimes stocks get sick even when their companies are in good health. Take biotech giant Amgen. Five years ago, its stock traded in the mid $60s; Monday it closed at $68. Over those same five years, Amgen's sales more than tripled, from $4.0 billion to $12.4 billion, and earnings per share nearly tripled, from $1.03 to $2.93 in 2005.
The upshot: Amgen (AMGN) is a growth stock trading at a value price. Analysts, on average, expect earnings of $3.66 per share this year and $4.14 next year. That puts Amgen's price-earnings ratio at 19 based on '06 estimates and at 16 based on '07 forecasts. At the same time, analysts expect earnings growth of 15% annually over the next few years.
Unlike most biotech companies, which drip gobs of red ink, Amgen is immensely profitable. Operating profit margins are about 40% of sales. Key blockbuster products include Aranesp, for anemia associated with kidney failure and chemotherapy; Neulasta, to help the immune system in chemotherapy patients; and Enbrel, for rheumatoid arthritis.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Amgen's pipeline of potential new products is rich, too. The company has several new drugs for cancer, as well as a medication for osteoporosis, in clinical trials. In addition, existing drugs are being tested for new applications. Most notably, Aranesp shows promise in preventing heart failure in patients with diabetes.
The stock has been beaten down this year in tandem with other biotech stocks. In addition, Amgen and Roche are battling in the courts over whether Roche can introduce a competitor to Aranesp in the U.S. But even giving Roche a 50% chance of winning that litigation, Bank of America analyst David Witzke recommends buying Amgen. "We believe Amgen should be a core holding in biotech and would look to use recent weakness to add to positions." Wachovia Securities analyst George Farmer on Monday upgraded Amgen to a buy, citing potential for its osteoporosis medication to be on the market in 2008 -- a year ahead of Wall Street expectations.
Amgen isn't just inventing new medications. Awash with cash, the company is buying up promising, small biotechs. It acquired Abgenix this year and Tularik last year. It recently set up a corporate venture fund to invest in other biotech firms. Amgen also has the heft to do its own marketing, as well as to market for smaller biotech companies, without having to enlist a big pharmaceutical firm.
Among the pessimists, Merrill Lynch analyst Eric Ende worries that in the short run Amgen could be a "value trap" -- that is a stock that seems cheap, but still falls. Ende is concerned about the Roche litigation and possible competition for other Amgen drugs. Plus, he sees little chance for any of Amgen's new drugs to be on the market until 2007.
Still, with the shares so cheap and the company so powerful, these are risks that may be worth accepting.
--Steven Goldberg
-
Starbucks BOGO and New Sweet and Spicy Drinks
For a limited time, Starbucks is announcing four new "swicy" drinks that are both spicy and sweet.
By Kathryn Pomroy Published
-
Stock Market Today: Dow Slips After Travelers' Earnings Miss
The property and casualty insurer posted a bottom-line miss as catastrophe losses spiked.
By Karee Venema Published
-
Stock Market Today: Dow Slips After Travelers' Earnings Miss
The property and casualty insurer posted a bottom-line miss as catastrophe losses spiked.
By Karee Venema Published
-
Stock Market Today: Stocks Stabilize After Powell's Rate-Cut Warning
The main indexes temporarily tumbled after Fed Chair Powell said interest rates could stay higher for longer.
By Karee Venema Published
-
Stock Market Today: Stocks Reverse Lower as Treasury Yields Spike
A good-news-is-bad-news retail sales report lowered rate-cut expectations and caused government bond yields to surge.
By Karee Venema Last updated
-
Stock Market Today: Nasdaq Leads as Magnificent 7 Stocks Rise
Strength in several mega-cap tech and communication services stocks kept the main indexes higher Thursday.
By Karee Venema Published
-
Stock Market Today: Stocks Tumble After a Hot Inflation Print
Equities retreated after inflation data called the Fed's rate-cut plans into question.
By Dan Burrows Published
-
Stock Market Today: Stocks End Mixed Ahead of Key Inflation Reading
Equities struggled before tomorrow's big Consumer Price Index report.
By Dan Burrows Published
-
Stock Market Today: Stocks Closed Mixed in Choppy Trading
Volatility returned as market participants adjusted their expectations for rate cuts.
By Dan Burrows Published
-
Stock Market Today: Stocks Rally After Blowout Jobs Report
Stocks soared into the weekend as investors brushed off strong payrolls data and lowered rate-cut expectations.
By Dan Burrows Published